interventional
N/A
1 country
21
To evaluate the efficacy of elranatamab in combination with mezigdomide and dexamethasone in RRMM patients in terms of achievement of MRD negativity
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 6, 2026
Actual (reported)MRD negativity rate defined as the percentage of participants who achieve MRD negativity at 10-5 by NGF in BM and ≥CR according to the IMWG criteria (APPENDIX 6)
Sustained MRD negativity at 10-5 at 24 months evaluated by NGF in BM
Percentage of patients converting to MRD negative at 10-5 at any time after ERI, evaluated by NGF in BM
Response rate, defined as the percentage of patients who achieve CR, VGPR, PR, MR, and SD as the best response to treatment based on confirmed response according to the IMWG criteria. ORR, defined as the percentage of subjects who achieve best response of partial response (PR) or better (PR, VGPR, or CR), based on confirmed response according to the IMWG criteria. TTR defined as the time from the date of elranatamab treatment initiation until the achievement of at least a PR
DoR, defined as the time from the achievement of at least a PR until the earliest date of documented disease progression by IMWG criteria. PFS, defined as the time from the date of elranatamab treatment initiation until the earliest date of documented disease progression by IMWG criteria or death due to any cause. OS, defined as the time from the date of elranatamab treatment initiation until the date of death due to any cause.
The safety profile of the study combination will be assessed based on: - Incidence of AEs. - Percentage of patients discontinuing therapy due to AEs. - Percentage of patients requiring dose modifications due to AEs. - Incidence of SAEs. - Changes in laboratory analytes from the hematology and blood chemistry panel. - Incidence of deaths and primary cause of death. Treatment safety will be assessed from C1D1 until 4 weeks after EoT
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
CC-92480
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
CAPSULE
View registry recordFormulated product
ELREXFIO 40 mg/mL solution for injection
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordFormulated product
ELREXFIO 40 mg/mL solution for injection
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordFormulated product
CC-92480
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
CAPSULE
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
CC-92480
Named ingredient: Mezigdomide
View registry recordELREXFIO 40 mg/mL solution for injection
Named ingredient: elranatamab
View registry recordELREXFIO 40 mg/mL solution for injection
Named ingredient: elranatamab
View registry recordCC-92480
Named ingredient: Mezigdomide
View registry recordRegistry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Hospital General Universitario Gregorio Maranon
Madrid, 28007, Spain
Hospital Costa Del Sol
Marbella, 29603, Spain
Clinica Universidad De Navarra
Madrid, 28027, Spain
Alfonso Santiago
First Submitted
July 6, 2026
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.
Clinica Universidad De Navarra
Pamplona, 31008, Spain
Consorci Sanitari Integral
L'hospitalet De Llobregat, 08906, Spain
Hospital Universitario De Cabuenes
Gijon, 33394, Spain
Hospital Clinic De Barcelona
Barcelona, 08036, Spain
Hospital Universitario 12 De Octubre
Madrid, 28041, Spain
Hospital Universitario Marques De Valdecilla
Santander, 39008, Spain
Hospital General Universitario Dr. Balmis
Alicante, 03010, Spain
Hospital Universitario Araba
Vitoria, 01009, Spain
Hospital Universitario Lucus Augusti
Lugo, 27003, Spain
University Clinical Hospital Virgen De La Arrixaca
Murcia, 30120, Spain
Hospital General Universitario De Albacete
Albacete, 02006, Spain
Hospital Universitario Central De Asturias
Oviedo, 33011, Spain
Hospital Universitario Virgen De Las Nieves
Granada, 18014, Spain
Complejo Asistencial Universitario De Salamanca
Salamanca, 37007, Spain
El Hospital Universitario De Gran Canaria Dr. Negrin
Las Palmas De Gran Canaria, 35010, Spain
Hospital Son Llatzer
Palma, 07198, Spain
Institut Catala D'oncologia
Badalona, 08916, Spain
Hospital Universitario Y Politecnico La Fe
Valencia, 46026, Spain